SARS-CoV-2 infection risk assessment from σCT
| Risk probability (CT) | Target | SARS-CoV-2 | Volunteer A | Volunteer B | Volunteer C | Volunteer D | Volunteer E | Volunteer F | Volunteer G | NTC |
|---|---|---|---|---|---|---|---|---|---|---|
| Pharyngeal, Trizol-manual | RdRP2 | 1.000 | 0.648 | 0.595 | 0.109 | 0.475 | 0.350 | 0.000 | 0.000 | 0.000 |
| E2 | 1.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| S2 | 1.000 | 0.000 | 0.003 | 0.061 | 0.007 | 0.002 | 0.007 | 0.000 | 0.012 | |
| N1 | 1.000 | 0.829 | 0.720 | 0.783 | 0.066 | 0.001 | 0.000 | 0.000 | 0.000 | |
| Pharyngeal, Trizol-Kit | RdRP2 | 1.000 | 0.457 | 0.312 | 0.337 | 0.763 | 0.999 | 0.029 | - | 0.350 |
| E2 | 1.000 | 0.571 | 0.498 | 0.000 | 0.015 | 0.000 | 0.000 | - | 0.053 | |
| S2 | 1.000 | 0.001 | 0.000 | 0.713 | 0.068 | 0.875 | 0.000 | - | 0.000 | |
| N1 | 1.000 | 0.000 | 0.001 | 0.179 | 0.046 | 0.000 | 0.000 | - | 0.008 | |
| Saliva, Trizol-Kit, 2-step qRT-PCR | RdRP2 | 1.000 | 0.588 | 1.000 | 0.004 | 0.028 | 0.118 | 0.036 | 0.418 | 0.059 |
| E2 | 1.000 | 0.000 | 0.179 | 0.000 | 0.000 | 0.000 | 0.000 | 0.001 | 0.000 | |
| S2 | 1.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.165 | 0.000 | 0.000 | 0.034 | |
| N1 | 1.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.002 | 0.000 | 0.000 | 0.000 | |
| Saliva, Trizol-Kit, 1-step qRT-PCR | RdRP2 | 1.000 | 0.872 | 0.000 | 0.990 | 1.000 | 1.000 | 0.005 | 1.000 | 0.207 |
| E2 | 1.000 | 0.000 | 0.504 | 0.000 | 0.000 | 0.001 | 0.868 | 0.060 | 0.000 | |
| S2 | 1.000 | 0.000 | 0.256 | 0.000 | 0.000 | 0.002 | 0.000 | 1.000 | 0.000 | |
| N1 | 1.000 | 0.761 | 0.761 | 0.066 | 0.023 | 0.974 | 0.023 | 0.997 | 0.000 |